Price growth drove India's pharmaceutical sales in 2022, shows data

Data shows that in calendar year 2022, price driven growth rate has been 6 per cent; growth from new products has been 1.7 percent, while volume growth has been zero

In Calendar 2022 (CY22), the Indian pharmaceutical (pharma) market expansion came from pricing, while volume growth remained muted, reveals data from market intelligence firm AIOCD Pharmasofttech AWACS (AIOCD-AWACS). 

Overall, the domestic pharma market grew 7.7 per cent in CY22.  

GlaxoSmithKline Pharmaceuticals’ (GSK Pharma’s) marquee antibiotic brand Augmentin emerged as the highest-selling drug in the country in CY22, with 27 per cent growth during the year.

Data shows that in CY22, the price-driven growth rate has been 6 per cent, growth from new products 1.7 per cent, while volume growth has been zero. 

Segments like gastroenterology (7.6 per cent), respiratory (7.1